Bellerophon Therapeutics, Inc.
BLPH
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.03% | 15.15% | 30.49% | 23.22% | -22.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -57.58% | -19.60% | -26.25% | 19.00% | 6.36% |
| Operating Income | 57.58% | 19.60% | 126.21% | -19.00% | -6.36% |
| Income Before Tax | 62.10% | 21.22% | 127.39% | -17.42% | -9.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 62.10% | -25.16% | 150.03% | -17.42% | -9.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.10% | -25.16% | 150.03% | -17.42% | -9.39% |
| EBIT | 57.58% | 19.60% | 126.21% | -19.00% | -6.36% |
| EBITDA | 57.41% | 19.38% | 126.33% | -19.50% | -6.46% |
| EPS Basic | 70.43% | 2.30% | 146.09% | -16.67% | -8.92% |
| Normalized Basic EPS | 68.27% | 38.52% | 125.23% | -16.70% | -8.78% |
| EPS Diluted | 69.87% | 2.30% | 145.69% | -17.78% | -8.37% |
| Normalized Diluted EPS | 68.27% | 38.52% | 124.63% | -16.70% | -8.78% |
| Average Basic Shares Outstanding | 28.15% | 28.14% | 8.51% | 0.63% | 0.41% |
| Average Diluted Shares Outstanding | 28.15% | 28.14% | 11.11% | 0.63% | 0.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
